Vivalis tech aids Singapore chikungunya breakthrough
This article was originally published in Scrip
A research consortium under Singapore's Agency for Science, Technology and Research, using technology from the French firm Vivalis, has discovered two antibodies with therapeutic potential against chikungunya.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.